LOS ANGELES, Sept. 10 /PRNewswire-FirstCall/ -- Flanked by prominent Board members Robert Windom, M.D. and Steven Phillips, M.D., Signalife's Dr. Lowell Harmison - in conjunction with inventor Dr. Budimir Drakulic - have this day initiated the product launch of the revolutionary, one-of-a-kind, FDA- approved, ambulatory 12-lead ECG cardiovascular monitor.
In private meetings throughout the United States over the next ten days, the trio of cardiovascular experts and Signalife's award-winning technology team will present the technologies to the marquee hospitals, facilities and physician-groups that Dr. Harmison has referred to since his recent appointment as acting CEO and President. Dr. Harmison has indicated that he anticipates the product launch to generate significant movement of both devices and technologies nationwide.
Dr. Harmison commented: "I am gratified that our Board has chosen to be personally involved in my initial product launch of the miraculous Fidelity 100 heart monitor. Additionally, it is extremely important and powerful to initiate our product launch with the actual inventor - and multiple Crump Award prize winner - Dr. Budimir Drakulic, whose inventions are legendary . . . from the Air Force EEG studies to winning the Frost & Sullivan Award after completing the initial Signalife device . . ., personally present at all of the institutions and locales."
"We will be visiting more than a dozen hospitals with thousands of beds and hundreds of physicians, beginning now, in cities nationwide. These are persons we know whose reputations and business successes precede them. I am personally excited about what I call our 'insider product launch' and I am thankful to Signalife's shareholders, Board members and staff for supporting the Company through the transition and thus making this possible. I will report back to the marketplace after this launch is completed.
"For more information on Dr. Harmison's initial product launch, whether from prospective purchasers of the technologies or from investors, Dr. Harmison has asked that the Company be contacted directly or through its investor relations personnel - particularly Mr. Kevin Kading.
Signalife, Inc. is an award-winning life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements:
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities an Exchange Commission.
|SOURCE Signalife, Inc.|
Copyright©2007 PR Newswire.
All rights reserved